Beyang Therapeutics runs an AI drug discovery platform called ExCEED that combines a proprietary database with computational simulation. Its pipeline includes an eye-drop candidate for retinal disease and a second-generation menin inhibitor for leukemia. Headquartered in Chengdu, Sichuan.